Navigation Links
Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market

WALTHAM, Mass., Dec. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of three blockbuster antibiotics -- levofloxacin, moxifloxacin and piperacillin/tazobactam -- will be the primary factors contributing to a decline of more than 15 percent in the community-acquired pneumonia drug market though 2018.

The new Pharmacor report entitled Community-Acquired Pneumonia finds that generic erosion of levofloxacin (Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit), moxifloxacin (Bayer/Merck/Shionogi's Avelox), and piperacillin/tazobactam (Pfizer's Zosyn and Taisho Toyama's Tazocin) will fuel a 1.6 percent annual decline in sales of antibiotics to treat community-acquired pneumonia. As a result, the market will decrease from more than $850 million in 2008 to more than $720 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although patent expiries in both the inpatient and outpatient settings will constrain the market, the launch of several new agents in the inpatient setting will help to partially offset losses in the overall market, according to the report.

"Two of the most clinically and commercially promising antibiotics in late-stage development are Johnson & Johnson/Basilea's ceftobiprole and Forest Laboratories/AstraZeneca/Takeda's ceftaroline, which are both broad-spectrum intravenous agents with anti-MRSA activity," said Decision Resources Analyst Jacqueline Lyons, MPH. "We forecast that these two agents combined will earn nearly $100 million in the community-acquired pneumonia market in 2018."

The report also finds that the community-acquired pneumonia market is characterized by untapped commercial opportunity for new drug development in the moderate to severe setting, for the treatment of resistant pathogens with agents that do not induce resistance, and for drugs with interchangeable intravenous and oral formulations to facilitate discharge of hospitalized patients.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources                        Decision Resources, Inc.
Christopher Comfort                       Elizabeth Marshall
781-296-2597                              781-296-2563         

SOURCE Decision Resources

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
3. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
4. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
5. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
6. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
7. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
8. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
9. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
10. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
11. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... 26, 2015 ) ... Administration of High Viscosity Drugs" report to ... announced the addition of the "Self Administration ... offering. --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" ...
(Date:11/25/2015)... Nov. 25, 2015 ... of the "Global Brain Monitoring Devices ... --> ) has announced ... Monitoring Devices Market 2015-2019" report to ... Markets ( ) has announced the ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... ... Pixel Film Studios is back again with ProPanel: Pulse . With ... Users have full control over angle of view, speed method, start point, end point, ... get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape masks, all ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed ... As people age, more care is needed, especially with Alzheimer’s, dementia and other ... are being overworked. The forgotten part of this equation: 80 percent of medical ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a ... component is distributed nationally, through a vast social media strategy and across a ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in America", ... delves into an array of issues that are presently affecting Americans. Dedicated to providing ... this show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
Breaking Medicine News(10 mins):